Inhibrx Biosciences opened lower at $88.56, compared with its previous close of $90.59. In the last trading session, the stock traded between $86.00 and $91.13. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Inhibrx Biosciences is now worth
$ 202.57
Giving a profit of
$ 102.57 (102.57%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 3 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-2.43 (-2.68%)
Day High
$91.13
Day Low
$86.00
Day Open
$88.56
Prev Close
$90.59
Volume
1,99,477
1W Return
1.18%
1M Return
-2.43%
3M Return
-4.43%
6M Return
-30.90%
1Y Return
13.26%
Fundamentals
Market Cap ($ Mn)
1,298
PE Ratio
-
PB Ratio
-
PEG Ratio
-
ROE
-205.11%
ROCE
-88.34%
EPS (TTM)
-
Investment Returns
1 Week
1.18%
1 Month
-2.43%
3 Months
-4.43%
6 Months
-30.90%
9 Months
7.53%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
1.3
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Mar 26
0.0
Jun 26
Updates
8Sep
Inhibrx INBRX-106 doubles response rate in HNSCC Phase 2 trial
INBRX-106 combined with Keytruda achieved a 48.3% confirmed objective response rate versus 26.5% for pembrolizumab alone in Phase 2 HNSCC trial. Median progression-free survival reached 9.6 months for the combination arm compared to 4.9 months for monotherapy. HPV-positive subgroup showed an 80% response rate with 30% complete responses, significantly outperforming the 33.3% control rate. Inhibrx plans to expand the trial with 50 HPV-positive patients and align with FDA for Phase 3 initiation. Shares declined 12.49% to $106.03 despite the positive clinical data.
2mo ago
16Jul
Inhibrx expands loan facility to $500.0 million with Oxford Finance
Inhibrx Biosciences amended its loan agreement with Oxford Finance LLC, increasing the total Credit Facility to $500.0 million. The amendment includes an immediate $100.0 million funding and warrants for 21,457 shares at $93.21 per share, with an option to draw an additional $225.0 million later. The funds will support the clinical development of ozekibart (INBRX-109) and INBRX-106.
3mo ago
15Jun
FDA accepts Inhibrx BLA for Ozekibart with PDUFA date April 14, 2027
Inhibrx Biosciences, Inc. announced that the FDA has accepted for filing its BLA for ozekibart (INBRX-109) for unresectable or metastatic conventional chondrosarcoma with a PDUFA goal date of April 14, 2027. The application is supported by the ChonDRAgon study, where ozekibart achieved a 52% reduction in the risk of disease progression or death and more than doubled median PFS to 5.52 months. If approved, ozekibart would be the first FDA-approved treatment for this indication.
